Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib

M J James; L G Cleland

doi:10.1136/jme.2003.004515

Article menu

Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts

PDF

Research ethics

Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib

Share this article

Click the icon of the social media platform on which you would like to share this article.

Share This Article:

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.

Your email: *

Your name: *

Send to: *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib

Message subject: (Your Name) has forwarded a page to you from Journal of Medical Ethics

Message body: (Your Name) thought you would like to see this page from the Journal of Medical Ethics web site.

Your personal message:

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Read the full text or download the PDF:

Log in using your username and password

For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?

Forgot your user name or password?

Other content recommended for you

The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs
M W van der Linden et al., Annals of the Rheumatic Diseases, 2008
Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children
Sean Turner et al., Archives of disease in childhood - Education & practice edition, 2004
Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
Mengtao Li et al., BMJ Open, 2020
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
Patricia M Kearney et al., BMJ, 2006
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
J M Brophy et al., Heart, 2006
Variability in the Response to Cyclooxygenase Inhibitors
Tilo Grosser, Journal of Investigative Medicine, 2015
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Julia Hippisley-Cox et al., BMJ, 2005
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages
Iryna Voloshyna et al., Journal of Investigative Medicine, 2016
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
A Lanas et al., Gut, 2006
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Julia Hippisley-Cox et al., BMJ, 2005

Log in using your username and password

Main menu

Log in using your username and password

You are here

Share this article

Email this article to a friend

Request permissions

Read the full text or download the PDF:

Log in using your username and password

Other content recommended for you